The study examined the cost of chemotherapy backbone with bevacizumab and chemotherapy backbone with cetuximab as first line therapies. Survival was nearly 30 months for each antibody group, according to the report.
The cost analysis found the average cost of one bevacizumab eight-week cycle per person was $9,324. On the other hand an eight-week cycle of cetuximab was $20,856.
Here are four costs to consider when comparing the two different treatments:
Bevacizumab
• Chemotherapy: $2,894
• Antibody: $33,500
• Hospital/acute care: $28,951
• Total cost: $66,075
Cetuximab
• Chemotherapy: $2,616
• Antibody: $71,718
• Hospital/acute care: $28,494
• Total cost: $105,339
More articles on gastroenterology:
American Journal of Gastroenterology features updates on biomarker advances
Cantel Medical reports net income of $12.3M in 3Q: 7 things to know
Underwriters of EndoChoice IPO to purchase additional shares
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
